“Neutral” was Reaffirmed on Merrimack Pharmaceuticals (NASDAQ:MACK) by Baird; with $7 Target.

June 27, 2018 - By Joshua Cleveland

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Corporate Logo

Reiterated Merrimack Pharmaceuticals (NASDAQ:MACK) Rating.

Baird have a $7 price target on Merrimack Pharmaceuticals (NASDAQ:MACK) shares. On Tuesday, 26 June the $67.18M market cap company have “Neutral” stock rating. This price target would indicate a potential 39.17 % upside on the stock.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Ratings Coverage

In total 3 analysts cover Merrimack Pharmaceuticals (NASDAQ:MACK). “Buy” rating has 0, “Sell” are 1, while 2 are “Hold”. (NASDAQ:MACK) has 0 bullish analysts. 4 are the (NASDAQ:MACK)’s ratings reports on Jun 27, 2018 according to StockzIntelligence Inc. On Monday, June 25 the firm has “Hold” rating by Cowen & Co given. In Tuesday, June 26 report Robert W. Baird maintained it with “Neutral” rating and $7 target. On Monday, June 25 the firm has “Underweight” rating given by JP Morgan.

MACK is touching $5.03 during the last trading session, after increased 1.51%.Merrimack Pharmaceuticals, Inc. has volume of 176,243 shares. Since June 27, 2017 MACK has declined 62.77% and is downtrending. The stock underperformed the S&P500 by 75.34%.

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)’s earnings release is expected by WallStreet on August, 8, according to Zacks. The earnings per share diference is $0.81 or 36.82 % up from last years number. Previous year: $-2.2; Analysts forcast: $-1.39. 4.51 % negative EPS growth is what analysts predict. $-1.33 earnings per share was announced for previous quarter.

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States.The company has $67.18 million market cap. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1.0.14 is the P/E ratio. The Company’s clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors.

For more Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) news released briefly go to: Nasdaq.com, Nasdaq.com, Schaeffersresearch.com, Benzinga.com or Benzinga.com. The titles are as follows: “Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher” released on June 25, 2018, “Mid-Morning Market Update: Markets Open Lower; Carnival Cuts Profit Forecast” on June 25, 2018, “2 Pharmaceutical Stocks Touching Record Lows” with a publish date: June 25, 2018, “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” and the last “10 Biggest Price Target Changes For Tuesday” with publication date: June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.